This study will be a single center, open label, randomized crossover, 2-period study conducted with 26 healthy male or female subjects. Subjects will be randomly assigned to 1 of the 2 possible treatment sequences as follows:~Fed/Fasted: surufatinib with food on Day 1 and surufatinib without food on Day 8~Fasting/Fed: surufatinib without food on Day 1 and surufatinib with food on Day 8
This study will be a 2-period study conducted with 26 healthy male or female subjects. Subjects will be randomly assigned to either receive a single dose of surufatinib with food in period 1, then without food in period 2, or vice-versa.